<DOC>
	<DOC>NCT02037984</DOC>
	<brief_summary>This study is designed to assess the effect of different dose levels of pneumococcal polysaccharide and adjuvant on the safety and immunogenicity of V114 in healthy adults and infants.</brief_summary>
	<brief_title>A Study to Evaluate the Safety, Tolerability and Immunogenicity of V114 in Healthy Adults and Infants (V114-004)</brief_title>
	<detailed_description>This study will consist of 2 stages. In stage 1, adult participants will be administered a single dose of V114. After completion of a review of safety data from the adult cohort, stage 2 of the study will enroll infants. Infants will receive a 4-dose schedule of either an active comparator or 1 of 5 dose/adjuvant combinations of V114.</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Pneumococcal Infections</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>Infants Healthy and able to attend all scheduled visits. Adults: Highly unlikely to conceive from vaccination through to 6 weeks after administration of the vaccine. Infants and Adults Prior administration of any pneumococcal vaccine, any nonlive vaccine within 14 days or any live vaccine within 30 days History of invasive pneumococcal disease Known hypersensitivity to any vaccine component Received systemic corticosteroids within 14 days of first vaccination Known or suspected impairment of immune function Febrile illness within 72 hours before vaccination Received blood transfusion or blood products within 30 days. Infants Mother has documented human immunodeficiency virus or is hepatitis B surface antigen positive Has asplenia or failure to thrive. Adults Is breastfeeding.</criteria>
	<gender>All</gender>
	<minimum_age>2 Months</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>